Most Recent
Janssen wins injunction against Juno in patent fight over generic Invega
Intellectual Property 2025-12-05 11:39 pm By Christine Caulfield

Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Sun Pharma defeats appeal over Otsuka’s injectable Abilify patent
Intellectual Property 2025-12-01 2:10 pm By Cindy Cameronne

The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Regeneron, Bayer settle appeal over launch of Sandoz’s Eylea biosimilar
Intellectual Property 2025-11-27 11:32 pm By Cindy Cameronne

Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Gillis Delaney dodges third-party costs bid in IP dispute
Intellectual Property 2025-11-04 11:56 pm By Cindy Cameronne

Law firm Gillis Delaney has defeated a bid for third-party costs by a warehouse management software company that was named in an intellectual property dispute, with a judge rejecting claims the firm was not authorised to act and acted unreasonably. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Isuzu’s appeal falls short in trade secrets spat with Directed Electronics
Intellectual Property 2025-11-03 11:55 pm By Cindy Cameronne

Isuzu has lost an appeal bid to shut down a lawsuit by car alarm company Directed Electronics over alleged trade secrets theft, after an earlier case left it with a $169 million damages bill.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Vehicle Monitoring must choose now between damages, account of profits in IP spat
Intellectual Property 2025-09-10 11:29 pm By Sam Matthews

A judge has ordered tech company Vehicle Management Systems to hurry up and choose between damages or an account of profits in its IP dispute with the city of Melbourne over a sensor-based system for timing parked vehicles.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Appeal filed in failed patent suit over Apple’s Touch ID, Face ID tech
Intellectual Property 2025-07-28 11:55 pm By Christine Caulfield

A patent holding company is challenging the dismissal of its infringement case over Apple’s Touch ID and Face ID technology.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Apple defeats patent infringement suit over Touch ID technology
Intellectual Property 2025-05-15 3:32 pm By Cindy Cameronne

Apple has defeated a claim by an Australian non-practicing entity that its patents for a remote entry system were infringed by the tech company’s Touch ID and Face ID technology. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Sandoz moves to block Amgen’s attorneys from prosecuting patents in IP spat
Intellectual Property 2025-05-06 11:41 pm By Andy Sidler

Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Novartis loses appeal over patent for heart drug Entresto
Intellectual Property 2025-03-24 11:50 pm By Cat Fredenburgh

Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis’ appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?